Lancashire and South Cumbria
Formulary
Formulary
6 Endocrine system
06-05-02 Antidiuretic hormone antagonists
| Demeclocycline |
|
Formulary
|
150mg Capsules
For SIADH only (unlicensed indication if not secondary to malignant disease). |
|
| Tolvaptan |
|
Formulary
|
Tablets 7.5mg, 15mg, 30mg, 45mg, 60mg, 90mg Autosomal dominant polycystic kidney disease (TA358) Treatment of hyponatremia in adults, secondary to the syndrome of inappropriate antidiuretic hormone secretion (SIADH) (No Blueteq form required). Treatment of SIADH in patients requiring cancer chemotherapy is NHS England commissioned Caution when prescribing - There is variation in the licensing of different products containing tolvaptan. Care should be taken to prescribe the correct product and dose for the indication. Products are available containing a combination of tablet strengths, these are licensed for polycystic kidney disease only. |
 LSCMMG: Tolvaptan NICE TA358 Tolvaptan for treating autosomal dominant polycystic kidney disease |
|
Links
- LSCMMG: Tolvaptan
LSCMMG: Trans Female Gender Dysphoria Information Sheet- LSCMMG: Trans Male Gender Dysphoria Information Sheet
- Medicines for children: Desmopressin for bedwetting
- MHRA: Desmopressin nasal spray: removal of nocturnal enuresis indication
- MHRA: Terlipressin: new recommendations to reduce risks of respiratory failure and septic shock in patients with type 1 hepatorenal syndrome
- NICE CG111: Bedwetting in under 19s
- NICE CG111: Bedwetting in under 19s
- NICE CG141: Acute upper gastrointestinal bleeding in over 16s: management
- NICE TA358 Tolvaptan for treating autosomal dominant polycystic kidney disease